Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)

Analysis of Liquidity Ratios
Quarterly Data

Low level of difficulty

Liquidity ratios measure the company’s ability to meet its short-term obligations.

Liquidity Ratios (Summary)

Regeneron Pharmaceuticals Inc., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Current ratio 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31 3.31 5.36 5.46 6.13
Quick ratio 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88 2.93 4.80 4.87 5.56
Cash ratio 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38 1.38 2.54 2.32 2.12

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities.

Current Ratio

Regeneron Pharmaceuticals Inc., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Current assets 7,109,100  6,651,000  6,928,600  6,447,600  5,719,583  4,814,917  4,544,732  4,335,030  4,135,742  3,860,051  3,669,263  3,180,188  3,501,689  3,209,225  3,133,379  2,915,095  2,675,640  2,283,341  2,310,714  2,167,461  2,200,512  1,918,695  1,871,049 
Current liabilities 1,765,400  1,713,100  1,511,400  1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724  811,162  734,990  601,542  536,134  654,660  410,200  351,578  305,068 
Liquidity Ratio
Current ratio1 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31 3.31 5.36 5.46 6.13
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17 1.45 1.52 1.85 1.76
AbbVie Inc. 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39 1.41 2.65 2.82 2.79
Allergan PLC 1.00 1.03 0.71 1.13 0.92 1.00 1.10 1.16 1.18 1.21 1.32 2.27 3.95 0.99 0.99 1.03 2.05 1.37 1.44 1.37 1.40 1.98 1.51
Amgen Inc. 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53 4.95 4.22 4.36 3.45
Biogen Inc. 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70 2.11 2.25 2.05 2.21
Bristol-Myers Squibb Co. 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94 1.73 1.75 1.80 1.86
Celgene Corp. 2.89 3.44 2.78 2.23 2.13 1.52 2.53 4.99 3.65 4.05 4.42 3.67 3.61 4.61 4.57 4.77 3.23 3.34 4.61 4.60 6.32 5.44 2.86
Eli Lilly & Co. 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41 1.09 1.60 1.77 1.97
Gilead Sciences Inc. 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70 3.07 2.07 2.49 2.19
Johnson & Johnson 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44 2.36 2.61 2.47 2.41
Merck & Co. Inc. 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61 1.77 1.34 1.87 1.84
Pfizer Inc. 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45 2.67 2.86 2.66 2.33

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 7,109,100 ÷ 1,765,400 = 4.03

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities.

Quick Ratio

Regeneron Pharmaceuticals Inc., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 1,384,800  1,045,500  1,708,500  1,467,700  1,087,843  917,876  1,019,491  812,733  792,065  744,313  811,773  535,203  920,359  646,508  604,214  809,102  654,587  390,554  507,907  648,719  646,554  600,135  461,858 
Marketable securities 1,493,100  1,624,200  1,523,900  1,342,200  1,104,309  765,642  605,461  596,847  586,879  523,537  495,311  503,481  488,032  398,656  244,965  236,121  241,055  213,694  234,257  251,761  395,650  216,774  186,275 
Accounts receivable, trade, net 2,027,700  1,920,200  1,728,400  1,723,700  1,665,737  1,534,324  1,531,936  1,538,642  1,532,693  1,420,403  1,339,794  1,343,368  1,332,071  1,431,966  1,450,572  1,152,489  1,088,207  1,071,665  1,015,962  739,379  673,915  664,075  801,773 
Accounts receivable from Sanofi 345,400  252,000  287,600  226,400  269,271  243,238  168,855  193,684  217,478  221,078  214,269  92,989  124,107  138,067  173,782  153,152  199,117  197,693  159,444  121,058  110,720  116,865  118,003 
Accounts receivable from Bayer 286,900  283,700  289,200  293,100  267,937  261,685  243,141  242,014  221,278  203,066  195,485  175,263  187,694  181,938  240,867  162,152  151,991  125,767  163,056  156,962  142,619  112,984  127,720 
Total quick assets 5,537,900  5,125,600  5,537,600  5,053,100  4,395,097  3,722,765  3,568,884  3,383,920  3,350,393  3,112,397  3,056,632  2,650,304  3,052,263  2,797,135  2,714,400  2,513,016  2,334,957  1,999,373  2,080,626  1,917,879  1,969,458  1,710,833  1,695,629 
 
Current liabilities 1,765,400  1,713,100  1,511,400  1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724  811,162  734,990  601,542  536,134  654,660  410,200  351,578  305,068 
Liquidity Ratio
Quick ratio1 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88 2.93 4.80 4.87 5.56
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45 0.76 0.78 1.13 1.07
AbbVie Inc. 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10 1.06 2.10 2.21 2.05
Allergan PLC 0.79 0.61 0.51 0.83 0.65 0.73 0.80 0.95 0.96 1.00 1.11 2.00 3.71 0.34 0.48 0.42 0.52 0.78 0.80 0.52 0.57 1.40 0.62
Amgen Inc. 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68 4.22 3.56 3.67 2.72
Biogen Inc. 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98 1.54 1.66 1.49 1.60
Bristol-Myers Squibb Co. 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44 1.28 1.30 1.35 1.38
Celgene Corp. 2.65 3.20 2.53 2.00 1.76 1.22 2.16 4.67 3.35 3.66 3.98 3.24 3.19 3.99 3.89 4.05 2.79 2.96 4.05 4.13 5.67 4.92 2.55
Eli Lilly & Co. 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95 0.77 1.11 1.20 1.35
Gilead Sciences Inc. 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17 2.56 1.51 1.96 1.64
Johnson & Johnson 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80 1.76 1.94 1.80 1.74
Merck & Co. Inc. 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09 1.19 0.80 1.14 1.23
Pfizer Inc. 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81 2.07 2.18 2.03 1.75

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 5,537,900 ÷ 1,765,400 = 3.14

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities.

Cash Ratio

Regeneron Pharmaceuticals Inc., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 1,384,800  1,045,500  1,708,500  1,467,700  1,087,843  917,876  1,019,491  812,733  792,065  744,313  811,773  535,203  920,359  646,508  604,214  809,102  654,587  390,554  507,907  648,719  646,554  600,135  461,858 
Marketable securities 1,493,100  1,624,200  1,523,900  1,342,200  1,104,309  765,642  605,461  596,847  586,879  523,537  495,311  503,481  488,032  398,656  244,965  236,121  241,055  213,694  234,257  251,761  395,650  216,774  186,275 
Total cash assets 2,877,900  2,669,700  3,232,400  2,809,900  2,192,152  1,683,518  1,624,952  1,409,580  1,378,944  1,267,850  1,307,084  1,038,684  1,408,391  1,045,164  849,179  1,045,223  895,642  604,248  742,164  900,480  1,042,204  816,909  648,133 
 
Current liabilities 1,765,400  1,713,100  1,511,400  1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724  811,162  734,990  601,542  536,134  654,660  410,200  351,578  305,068 
Liquidity Ratio
Cash ratio1 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38 1.38 2.54 2.32 2.12
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07 0.42 0.45 0.72 0.69
AbbVie Inc. 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72 0.73 1.56 1.62 1.46
Allergan PLC 0.47 0.24 0.20 0.33 0.19 0.28 0.35 0.65 0.64 0.67 0.86 1.68 3.41 0.06 0.22 0.13 0.25 0.20 0.28 0.05 0.08 1.03 0.11
Amgen Inc. 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28 3.86 3.28 3.33 2.41
Biogen Inc. 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11 0.83 0.96 0.82 0.79
Bristol-Myers Squibb Co. 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99 0.88 0.89 0.92 0.94
Celgene Corp. 2.18 2.53 1.94 1.49 1.19 0.76 1.52 4.03 2.90 3.13 3.37 2.69 2.59 3.22 3.11 3.33 2.39 2.53 3.49 3.57 4.91 4.17 2.11
Eli Lilly & Co. 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50 0.43 0.64 0.69 0.79
Gilead Sciences Inc. 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52 1.76 1.04 1.41 1.09
Johnson & Johnson 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31 1.32 1.44 1.30 1.23
Merck & Co. Inc. 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76 0.84 0.55 0.75 0.91
Pfizer Inc. 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37 1.67 1.68 1.55 1.37

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,877,900 ÷ 1,765,400 = 1.63

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities.